TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 6 PATIENT WITH TRIPLE THERAPY PEG-IFN, RIBAVIRIN AND SOFOSBUVIR: CASE REPORT AND REVIEW OF LITERATURE
Journal of Medicine and Pharmacy2017pp. 112–114
Abstract
The author presents a case with chronic hepatitis C, genotype 6, treated with triple regime: Peg-IFN combined to ribavirin and sofosbuvir. After 3 months of therapy and 3 months follow up, patient has good clinical and virological response (SVR 12). Some results of similar studies in Vietnam and abroad, especially the studies concerning the new agents DAAs were also presented, analysed and compared with author’s results. Key words: Hepatitis C, treatment, Peg-IFN, Ribavirin, Sofosbuvir
Related Papers
- → Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)(2020)5 cited
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin(2016)
- PE-074 : Efficacy and Safety of Sofosbuvir and Ribavirin in Treatment of HCV Genotype 2(2017)
- → Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon-Α in Patients with HCV Genotype 3A Infection(2021)